Neurocrine Biosciences, Inc. · NBIX · FY2026 Q2 · Calendar Q3 2026
Neurocrine raises INGREZZA outlook as VYKAT XR integration begins
Neurocrine's commercial momentum across INGREZZA, CRENESITY and newly acquired VYKAT XR, together with a higher INGREZZA outlook, supports a constructive operating picture. The durability of that trajectory depends on payer access, continued product adoption and successful integration, while pipeline milestones remain uncertain.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about NBIX FY2026 Q2
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management raised FY2026 INGREZZA revenue guidance versus the prior quarter's reaffirmed outlook. The call also described integration of the acquired VYKAT XR franchise and highlighted longer-term pipeline programs; the supplied analysis does not indicate a comparable change to those programs' clinical outcomes.
Guidance delta
Raised: FY2026 INGREZZA revenue guidance is now $2.825–$2.875 billion, compared with $2.7–$2.8 billion in the prior-quarter analysis.
Key takeaways
- Management attributed commercial growth to INGREZZA, CRENESITY and VYKAT XR.
- INGREZZA's FY2026 revenue outlook was raised.
- The VYKAT XR acquisition adds a rare-disease franchise, with commercial integration underway.
- Management highlighted Phase 3 data for osavampator and dereclidine in 2027; these remain future clinical milestones.
Management priorities
- Expand new-patient starts and prescriber reach for INGREZZA.
- Continue CRENESITY adoption and grow its prescriber base.
- Integrate and scale VYKAT XR commercially.
- Advance pipeline programs, including planned Phase 3 readouts and the obesity CRF2 program.
Follow NBIX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationNeurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing…
Historical context
All NBIX earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | FY2026 Q3 · Calendar Q4 2026 | -1.2% | -1.0% | Vertex lifts 2026 outlook as CF franchise and newer products support growth |
| JAZZ Jazz Pharmaceuticals plc | FY2026 Q3 · Calendar Q4 2026 | +4.2% | -0.7% | Jazz lifts 2026 revenue outlook as Ziihera launch adds momentum |
| BMRN BioMarin Pharmaceutical Inc. | FY2026 Q3 · Calendar Q4 2026 | +376.0% | -1.8% | BioMarin’s Q3 growth meets a lower full-year outlook |
| IDXX IDEXX Laboratories, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.2% | +21.8% | IDEXX Raises FY2026 Outlook on Diagnostics and Software Growth |
| AXSM Axsome Therapeutics, Inc. | FY2026 Q3 · Calendar Q4 2026 | +60.6% | -5.8% | Axsome’s Q3 growth broadens, while reimbursement and trial execution remain key tests |
| TEM Tempus AI, Inc. | FY2026 Q3 · Calendar Q4 2026 | +174.7% | +8.7% | Tempus Q3 growth broadens across diagnostics and data |
Latest beats and misses
Who reports nextBeat on EPS
- TSEMFY2026 Q3 · November 2, 2026+7.5% EPS-6.7% move
- CLXFY2027 Q1 · November 2, 2026+44.9% EPS+2.2% move
- AAPLFY2026 Q4 · November 2, 2026+3.0% EPS-1.8% move
- PLTRFY2026 Q3 · November 2, 2026+8.3% EPS-3.1% move
- ETRFY2026 Q3 · November 2, 2026+14.5% EPS-0.2% move
- OFY2026 Q3 · November 2, 2026+5.7% EPS+1.1% move
Missed on EPS
- VRTXFY2026 Q3 · November 2, 2026-1.2% EPS-1.0% move
- PEGFY2026 Q3 · November 2, 2026-3.4% EPS+0.1% move
- RYAAYFY2027 Q2 · November 2, 2026-0.3% EPS+2.9% move
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
Get the NBIX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-07-30T22:14:13.884914+00:00
- FN2 earnings calendar · 2026-09-04T01:23:15.205020+00:00
- Polygon adjusted daily market bars · 2026-11-03T09:00:46.655386+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-03T09:00:46.652548+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-03. For educational purposes only; not investment advice.